Biotech Values

[loparn]

WntResearch, WNT.ST is an example of an extremely fine risk/reward in a Phase Ib-project Foxy-5

http://www.infoom.se/mysite/index.php?sida=80579&user=9801

Sooner or later the market will understand why Foxy-5 could be the first antimetastasis drug ever.

These Kaplan-Meier-curves comparing Foxy-5:s "target" molecule Wnt-5a in breast cancer patients show the potential http://cancerres.aacrjournals.org/content/canres/62/2/409/F6.large.jpg?width=800&height=600&carousel=1
...if Foxy-5 could do the same in patients with low or no Wnt-5a expression in their primary tumors.

The curves show a difference of over 8 years in progressionfree median survival depending on the natural Wnt-5a expression.